Spotlight
Twitter feed
Attend the #AACR23 Cancer and Biomedical Research Career Fair on April 15 in Orlando. Scientists at all career levels can meet with organizations seeking to fill scientific positions. Upload your CV/resume and attend for a chance to win great prizes.
https://t.co/tFdKfpdcKz
Now that #GI23 is complete, catch up on all the practice-changing research presented at the Symposium with in-depth coverage from #ASCODailyNews: https://t.co/s5dy9JGmaa
Today, the @US_FDA granted accelerated approval to pirtobrutinib, a targeted therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more systemic therapies.
FDA grants accelerated approval to pirtobrutinib
FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma
bit.ly
Today the @US_FDA approved the targeted therapeutic elacestrant to treat certain postmenopausal women or adult men with advanced or metastatic ER-positive, HER2-negative,ESR1-mutated breast cancer after one or more lines of endocrine therapy.
FDA approves elacestrant for ER-positive
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
bit.ly
New #ColonCancer research: Investigators found higher inflammation after diagnosis was associated with an increased risk of recurrence and death. Research led by @DanaFarber's Jeffrey Meyerhardt, MD, in @JAMAOnc
CC: @EnCheng23 @DFarberYoungCRC
Read more:
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer
This cohort study assesses the association between survival outcomes and levels of inflammatory biomarkers after diagnosis with stage III colon cancer...
ms.spr.ly
For #ASCODailyNews, Drs. Jeanny Aragon-Ching and @PGrivasMDPhD present the most recent progress made in determining appropriate first-line treatment for cisplatin-ineligible patients with mUC: https://t.co/yvRj5nz5HP #GU23 #gucsm
While the past decade has brought progress against cervical cancer, challenges remain, especially for older women and those in lower- and middle-income countries. Learn more on the #AACRBlog. @CancerTodayMag @CEBP_AACR #CervicalCancerAwarenessMonth https://t.co/zSN7vo8fFb
Register by February 1 to get the lowest rates for the AACR Special Conference on Advances in Prostate Cancer Research (March 15-18, 2023; Denver), chaired by Cory Abate-Shen, @felixfengmd, and Scott A. Tomlins. Learn more:
https://t.co/tQXBfwHqjc
#AACRprostate23
“I imagine you setting sail off into the sunset, taking the cancer with you, with me safely ashore, waving goodbye,” writes Dana-Farber patient Julie Devaney Hogan as she prepares for a double mastectomy. Read more @TODAYshow:
https://t.co/diW5I0lJjG
Deborah Schrag, David @DeNardoLabWUSM, @tomi_akinyemiju, Robert Yarchoan, and @TeresaZimmers will present their cutting-edge research in the Opening Plenary Session at the AACR Annual Meeting 2023 (April 14-19, Orlando, Florida). Learn more:
https://t.co/61tkAE6yNJ
#AACR23
Announcements
Donor highlight
Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.
